Exact Mass: 557.0667

Exact Mass Matches: 557.0667

Found 30 metabolites which its exact mass value is equals to given mass value 557.0667, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

6-CFDA N-succinimidyl ester

2,5-Dioxopyrrolidin-1-yl 3,6-bis(acetyloxy)-3-oxo-3H-spiro[2-benzofuran-1,9-xanthene]-6-carboxylic acid

C29H19NO11 (557.0958)


D019995 - Laboratory Chemicals > D007202 - Indicators and Reagents > D049408 - Luminescent Agents D004396 - Coloring Agents > D005456 - Fluorescent Dyes > D005452 - Fluoresceins

   

8-Hydroxyluteolin 4-methyl ether 8-glucoside-3-sulfate

8-Hydroxyluteolin 4-methyl ether 8-glucoside-3-sulfate

C22H21O15S (557.0601)


   

7-deoxo-7-hydroxy-4-demethylrebeccamycin

7-deoxo-7-hydroxy-4-demethylrebeccamycin

C26H21Cl2N3O7 (557.0756)


   

Tetra-Ac-Clionamide

Tetra-Ac-Clionamide

C25H24BrN3O7 (557.0798)


   
   

Phenolphthalein bisphosphate pyridine salt

Phenolphthalein bisphosphate pyridine salt

C25H21NO10P2 (557.0641)


   

5-(((2,5-DIOXOPYRROLIDIN-1-YL)OXY)CARBONYL)-3-OXO-3H-SPIRO[ISOBENZOFURAN-1,9-XANTHENE]-3,6-DIYL DIACETATE

5-(((2,5-DIOXOPYRROLIDIN-1-YL)OXY)CARBONYL)-3-OXO-3H-SPIRO[ISOBENZOFURAN-1,9-XANTHENE]-3,6-DIYL DIACETATE

C29H19NO11 (557.0958)


   

5-Carboxyfluorescein diacetate N-succinimidyl ester

5-Carboxyfluorescein diacetate N-succinimidyl ester

C29H19NO11 (557.0958)


   

Canertinib dihydrochloride

Canertinib dihydrochloride

C24H27Cl3FN5O3 (557.1163)


C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D000777 - Anesthetics C274 - Antineoplastic Agent > C163758 - Targeted Therapy Agent > C163952 - EGFR-targeting Agent C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C1967 - Tyrosine Kinase Inhibitor D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor D020011 - Protective Agents > D002316 - Cardiotonic Agents D000970 - Antineoplastic Agents D002317 - Cardiovascular Agents

   

N-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoroundecyl)maleimide

N-(4,4,5,5,6,6,7,7,8,8,9,9,10,10,11,11,11-Heptadecafluoroundecyl)maleimide

C15H8F17NO2 (557.0284)


   

alpha-beta Methylene ADP-ribose

alpha-beta Methylene ADP-ribose

C16H25N5O13P2 (557.0924)


   

3-O-(beta-D-Glucopyranuronosyl)-4-O,6-O-disulfo-2-(acetylamino)-2-deoxy-beta-D-galactopyranose

3-O-(beta-D-Glucopyranuronosyl)-4-O,6-O-disulfo-2-(acetylamino)-2-deoxy-beta-D-galactopyranose

C14H23NO18S2 (557.0357)


   

ADP-D-ribose(2-)

ADP-D-ribose(2-)

C15H21N5O14P2-2 (557.056)


COVID info from COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS

   

N10-(bromoacetyl)-5,8-dideazafolate

N10-(bromoacetyl)-5,8-dideazafolate

C23H20BrN5O7-2 (557.0546)


   

(2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid

(2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid

C14H23NO18S2 (557.0357)


   

(2R,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid

(2R,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-6-(hydroxymethyl)-5-sulfooxyoxan-4-yl]oxy-3,4-dihydroxy-5-sulfooxyoxane-2-carboxylic acid

C14H23NO18S2 (557.0357)


   

[(1->2)-ADP-alpha-D-ribose]n

[(1->2)-ADP-alpha-D-ribose]n

C15H21N5O14P2-2 (557.056)


   

7-Phenyl-5-[(4-sulfophenyl)imino]-5,7-dihydrobenzo[a]phenazine-3-sulfonic acid

7-Phenyl-5-[(4-sulfophenyl)imino]-5,7-dihydrobenzo[a]phenazine-3-sulfonic acid

C28H19N3O6S2 (557.0715)


   

D-ribofuranosyl-ADP(2-)

D-ribofuranosyl-ADP(2-)

C15H21N5O14P2-2 (557.056)


   

IdoA(a1-3)GalNAc4S6S

IdoA(a1-3)GalNAc4S6S

C14H23NO18S2 (557.0357)


   

IdoA2S(a1-3)GalNAc4S

IdoA2S(a1-3)GalNAc4S

C14H23NO18S2 (557.0357)


   

IdoA2S(a1-3)GalNAc6S

IdoA2S(a1-3)GalNAc6S

C14H23NO18S2 (557.0357)


   

GlcA2S(b1-3)GalNAc6S

GlcA2S(b1-3)GalNAc6S

C14H23NO18S2 (557.0357)


   

GlcA(b1-3)GalNAc4S6S

GlcA(b1-3)GalNAc4S6S

C14H23NO18S2 (557.0357)


   

GlcA2S(b1-3)GalNAc4S

GlcA2S(b1-3)GalNAc4S

C14H23NO18S2 (557.0357)


   

(2R,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-5-sulfooxy-6-(sulfooxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

(2R,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2-hydroxy-5-sulfooxy-6-(sulfooxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid

C14H23NO18S2 (557.0357)


   

ADP-D-ribose(2-)

ADP-D-ribose(2-)

C15H21N5O14P2 (557.056)


A nucleotide-sugar oxoanion that is the dianion of ADP-D-ribose(2-) arising from deprotonation of the phosphate OH groups; major species at pH 7.3.

   

DO-264

DO-264

C23H20Cl2F3N5O2S (557.0667)


DO-264 is a selective and in vivo-active inhibitor of Abhydrolase Domain Containing 12 (ABHD12), with an IC50 of 11 nM.

   

DQP-1105

DQP-1105

C29H24BrN3O4 (557.095)


DQP-1105 is a potent noncompetitive NMDA receptor antagonist. DQP-1105 inhibits GluN2C- and GluN2D-containing receptors (IC50=7.0 and 2.7 μM, respectively). The IC50 values are at least 50-fold lower than those for recombinant GluN2A-, GluN2B-, GluA1-, or GluK2-containing receptors[1].